Browsing category:

Antibiotic


The Threat of Antibiotic Resistance

Biapenem CAS No: 120410-24-4 Doripenem CAS No: 148016-81-3 Ertapenem CAS No: 153832-46-3 Imipenem CAS No: 74431-23-5 Meropenem CAS No: 96036-03-2 Panipenem CAS No: 87726-17-8 A new publication is out called “May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations” and it highlights the antibiotic-resistant infections which are being seen for the 1st[…]

Read More

Antibiotics, such as Amoxicillin, are extremely effectual when used appropriately prior to surgical procedures. The expiration of the potent antimicrobial drug Moxatag, also known as Amoxicillin, on October 13, 2020, paves the way for additional development of this generic powerhouse. Study results recently released in Infection Control and Hospital Epidemiology reveal that timing is crucial[…]

Read More

Midstage trial data of a Pyrazinamide cocktail to treat TB has offered encouraging news for patients with the HIV infection. Coined PaMZ, this drug trio includes Pyrazinamide and two antibacterial drugs, with results going into the Phase III trial looking promising. The antibacterial drugs are PA-824, which was initially developed by the Novartis and the[…]

Read More

The end of June 2014 brought exciting news for Insmed’s liposomal Amikacin, known as the brand name Arikace, with a Breakthrough Status award from the FDA. Amikacin was specifically designated Breakthrough Status for treatment refractory nontuberculous mycobacterial lung disease in adult patients. As an inhaled antibiotic Amikacin is effectual for treating chronic nontuberculous mycobacterial lung[…]

Read More

Exciting news was announced at the end of May 2014 from Durata Therapeutics with the FDA approval of Dalbavancin, their novel antibiotic treatment. Known as the brand name Dalvance, the FDA nod for Dalbavancin meets a current need for new, safe and efficacious antibiotics. Dalbavancin is officially approved to treat skin structure and bacterial skin infections[…]

Read More

Daptomycin, recognized as the brand name antibiotic Cubicin, has a patent expiration of September 24, 2019. Cubist Pharmaceutical markets Cubicin and they recently released a report revealing surprisingly weak sales. Initially Cubist reported strong sales of Daptomycin for the first quarter of 2013, with an overall rise in their revenues due to this potent antibiotic.[…]

Read More

On February 10, 2104 a substantial financial deal was announced by Melinta Therapeutics involving their projected blockbuster antibiotic Delafloxacin. A whopping 70 million dollar Series 3 equity financing deal was revealed, with various investors taking part, including Vatera Healthcare Partners. This extraordinary financing will be appropriated largely to advance the continued development, assessment and eventual[…]

Read More

As an aminoglycoside antibiotic effective for treating a wide variety of infections, Tobramycin CAS# 32986-56-4 is an integral medication that affects a vast number of patients. Tobramycin is particularly effectual for treating Gram-negative infections and certain Pseudomonas. The recent shortage of this crucial antibiotic has been felt for patients who take Tobramycin, either as an[…]

Read More

When penicillin was discovered in 1928 by Alexander Fleming no one knew quite how great of an impact this drug would make on the world. The actual use of penicillin to treat infection did not begin until the mid-1940s,  when a powdery form of this medication was developed by Howard Florey and Ernst Chain.  The[…]

Read More